US OptionsDetailed Quotes
CTVA241220P80000
- 18.98
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
18.98Open18.98Pre Close0 Volume0 Open Interest80.00Strike Price0.00Turnover7056.80%IV-6.16%PremiumDec 20, 2024Expiry Date22.52Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9832Delta0.0048Gamma2.53Leverage Ratio-97.6216Theta0.0000Rho-2.49Eff Leverage0.0001Vega
Corteva Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$Citigroup (C.US)$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock (BLK.US)$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life (GL.US)$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...
Gapping up
$Citigroup (C.US)$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock (BLK.US)$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life (GL.US)$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...
27
1
6
Corteva's rising ROCE and efficient capital use are promising, but growing current liabilities may pose new risks. Despite this, the stock has given a decent 23% return over the past three years, indicating these developments are gaining deserved attention.
1
Corteva's high P/E ratio is sustained by its projected growth surpassing the broader market. Shareholders are at ease with the P/E, confident in the company's future earnings. The share price isn't anticipated to drop significantly soon under these conditions.
The CEO of Lavie Bio, Amit Noam, expressed satisfaction at achieving this milestone with Corteva, stating that the agreement showcases Lavie Bio's technological capabilities and enables the swift introduction of groundbreaking ag-biological solutions.
Corteva's guidance dispels concerns of lower earnings due to falling crop prices. Aptiv's 2024 forecast predicts a 7% sales growth despite stagnant global auto production. TD Cowen analyst Gautam Khanna deems Trane's results as 'good enough', rating the stock as Buy with a $235 price target.
RECAP
US stocks rebounded from Wednesday's slump that was fueled by Federal Reserve Jerome Powell's comments signaling policymakers aren't likely to start cutting interest rates in March.
The $S&P 500 Index (.SPX.US)$ rose 1.25% while the $Nasdaq Composite Index (.IXIC.US)$ also gained 1.30%. The $Dow Jones Industrial Average (.DJI.US)$ increased almost 1%.
Market attention refocused on earnings, with three of the Magnifice...
US stocks rebounded from Wednesday's slump that was fueled by Federal Reserve Jerome Powell's comments signaling policymakers aren't likely to start cutting interest rates in March.
The $S&P 500 Index (.SPX.US)$ rose 1.25% while the $Nasdaq Composite Index (.IXIC.US)$ also gained 1.30%. The $Dow Jones Industrial Average (.DJI.US)$ increased almost 1%.
Market attention refocused on earnings, with three of the Magnifice...
13
1
6
the mostInsider transactions at Corteva reflect optimism and confidence in the stock's future, evidenced by a lack of sales and premium prices paid. However, increased insider ownership would further align company leaders with shareholders.
Analysts believe that the increased competition faced by Corteva in South America will have a negative impact on their stock performance. The current destocking cycle is also expected to negatively affect the stock's performance.
Corteva's rising ROCE suggests that it is becoming more efficient, and this is possibly being reflected in its stock performance. Analysts believe these trends might continue and hence it could be worth observing into the future.
3
Pre-Market Stock Movers
Gapping up
$Lowe's Companies (LOW.US)$ stock rose 0.9% after Bernstein upgraded its stance on the home improvement retailer to ‘outperform’ from ‘market perform’, saying tailwinds are starting to add up.
$Airbnb (ABNB.US)$ stock rose 5.7% and $Blackstone (BX.US)$ stock added 3.8% with the two companies set to join the benchmark S&P 500 index.
$Oracle (ORCL.US)$ stock rose 1.9% after Barclays upgrade...
Gapping up
$Lowe's Companies (LOW.US)$ stock rose 0.9% after Bernstein upgraded its stance on the home improvement retailer to ‘outperform’ from ‘market perform’, saying tailwinds are starting to add up.
$Airbnb (ABNB.US)$ stock rose 5.7% and $Blackstone (BX.US)$ stock added 3.8% with the two companies set to join the benchmark S&P 500 index.
$Oracle (ORCL.US)$ stock rose 1.9% after Barclays upgrade...
25
6
No comment yet
Peanny : Based on Lies…. The truth is on its way.